Connect with us

Technology

Elsevier adds half a million records from ClinicalTrials.gov to Embase, enabling a seamless search experience in the world’s most comprehensive biomedical database

Published

on

Data from studies conducted in more than 200 countries supports greater access to research and facilitates systematic reviews, clinical trial design, medical device approvals and improved drug safety

LONDON, May 6, 2025 /PRNewswire/ — Elsevier, a global leader in information and analytics, is announcing the addition of half a million records from ClinicalTrials.gov to its leading biomedical literature database, Embase. The integration will enable researchers to seamlessly view high-quality information on clinical research studies and their results alongside the peer-reviewed literature, in-press publications and conference abstracts already available in Embase. Researchers will be able to conduct more comprehensive evidence and literature searches while having the confidence they will never miss important updates relevant to their drug, therapy, or medical device.

Clinical trials data is a vital component of biomedical literature search, helping pharmaceutical and medical device companies stay informed about the latest scientific advancements, regulatory requirements, and competitive insights to support evidence-based decision-making. However, gathering data from multiple sources is currently prone to errors and is time-consuming, such as the duplication of search results, which slows research and regulatory processes. As new therapies and devices are developed and R&D organizations seek collaborative partners, they must undertake thorough searches and justifications of evidence. This process becomes challenging when data must be sourced from differing platforms, and regulatory and compliance requirements continue to evolve.

The addition of ClinicalTrials.gov data to Embase will improve researcher workflows by making clinical data searchable within Embase’s user-friendly interface. By presenting all biomedical evidence in a single platform, Embase enables researchers to better align and analyze search results, as well as export data into a citation manager. Clinical trials will be automatically indexed using the latest Emtree vocabulary, ensuring they are indexed accurately based on their title, a brief summary and detailed description. This new integration continues to support multiple use cases that Embase delivers to users, including to medical affairs, to understand clinical endpoints, outcomes and patient populations for already-approved drugs, providing competitive intelligence, supporting medical device development and approval, improving clinical trial design, and improving drug safety.

By late 2025, Embase will further expand its ClinicalTrials.gov coverage to include eligibility criteria and study plan information, reinforcing its role as a comprehensive platform for accessing both published literature and clinical trial registry data.

Mirit Eldor, Managing Director of the Life Sciences business at Elsevier, said, “Researchers are under increasing pressure to conduct comprehensive evidence searches with accuracy and efficiency, ensuring no critical information is overlooked. The incorporation of clinical trials data into Embase is the latest example of Elsevier’s commitment to developing innovative solutions that enhance researchers’ workflows. With access to comprehensive, high-quality data, researchers can reduce time spent on manual searches, while making more informed decisions that ensure the integrity of their company’s drug, therapy, or medical device. We have had many requests from customers to add Clinical Trials data into Embase and I’m delighted that we are able to improve the value that we deliver to our customers”

https://www.elsevier.com/products/embase

About Elsevier

A global leader in advanced information and decision support, Elsevier helps to advance science and healthcare, to advance human progress. We do this by facilitating insights and critical decision-making with innovative solutions based on trusted, evidence-based content and advanced AI-enabled digital technologies.

We have supported the work of our research and healthcare communities for more than 140 years. Our 9,700 employees around the world, including 2,300 technologists, are dedicated to supporting researchers, librarians, academic leaders, funders, governments, R&D-intensive companies, doctors, nurses, future healthcare professionals and educators in their critical work. Our 3,000 scientific journals and iconic reference books include the foremost titles in their fields, including Cell Press, The Lancet and Gray’s Anatomy. Together with the Elsevier Foundation, we work in partnership with the communities we serve to advance inclusion in science, research and healthcare in developing countries and around the world.

Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. For more information on our work, digital solutions and content, visit www.elsevier.com.

Logo – https://mma.prnewswire.com/media/2628519/5299491/Elsevier_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/elsevier-adds-half-a-million-records-from-clinicaltrialsgov-to-embase-enabling-a-seamless-search-experience-in-the-worlds-most-comprehensive-biomedical-database-302445217.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Media Advisory – Minister Hodgson to deliver keynote speech on One Year of Nation Building

Published

on

By

TORONTO, April 22, 2026 /CNW/ – The Minister of Energy and Natural Resources, the Honourable Tim Hodgson, will speak at the Empire Club of Canada regarding this past year’s accomplishments and future strategic directions.

Date: April 24, 2026

Time: 11:30 a.m. ET

All accredited media are asked to register using the Empire Club’s press accreditation and registration form. Details on how to participate will be provided upon registration.

Follow Natural Resources Canada on LinkedIn.

SOURCE Natural Resources Canada

Continue Reading

Technology

Harness Delivers Unified AI Intelligence Across Software Delivery with Google Cloud

Published

on

By

Harness integrates Google Cloud’s Developer Connect into its Software Delivery Knowledge Graph to give engineering teams smarter, faster AI-driven insights

SAN FRANCISCO, April 22, 2026 /PRNewswire/ — Harness, the AI Software Delivery Platform™ company, today announced that it will bring together Harness’s Software Delivery Knowledge Graph and Google Cloud’s Developer Connect. The initiative gives joint customers a unified, AI-ready view of their entire software delivery lifecycle, and the intelligence to act on it with confidence.

The announcement was made at Google Cloud Next, where Harness also won the 2026 Google Cloud Technology Partner of the Year Award in the Application Development – DevOps category.

The Missing Piece in AI Software Delivery

Modern software delivery environments are inherently complex. Pipelines, services, build and deploy infrastructure, artifacts, and dependencies are deeply interconnected — and the data that describes how they relate to one another is scattered across dozens of tools. As organizations accelerate their adoption of AI-powered engineering, that fragmentation becomes a critical liability. AI is only as effective as the context it can access, and today, most AI agents are operating with an incomplete picture.

Harness is addressing this challenge head-on. By integrating Google Cloud Developer Connect insights into the Harness Software Delivery Knowledge Graph, joint customers gain a continuously updated, relationship-aware model of their software delivery environment that spans both platforms, bridging the visibility gap between development and production so that AI agents can operate with complete and reliable context. For engineering teams, this translates directly to making decisions grounded in situational awareness rather than generic training data, allowing them to execute complex workflows with greater accuracy.

Where the Partnership Comes to Life

For joint customers of Harness and Google Cloud, this integration means Harness AI can now make smarter, faster decisions on their behalf. By bringing together deployment event logs, runtime data, and application dependency information from Google Cloud into the Harness Software Delivery Knowledge Graph, teams gain a continuously updated, comprehensive view of their software delivery environment. When an issue arises, engineers can diagnose and remediate faster, trace problems back to specific source files or infrastructure, and link artifacts to the teams responsible for them, without having to manually piece together context from multiple systems.

The result is AI that works harder for customers. With richer context available upfront, AI agents can operate more efficiently, delivering answers and recommendations that reflect the true state of the environment. Everything teams need is in one place, and their AI has everything it needs to act on it confidently.

Security is central to how this integration was built. Data shared between Harness and Google Cloud is governed by enterprise-grade access controls, ensuring the right information reaches the right people within the guardrails organizations require.

“AI is only as powerful as the context behind it. Without it, teams fall into the AI Velocity Paradox: moving code faster than ever, but risking shipping software that is unverified, insecure, and unreliable,” said Jyoti Bansal, co-founder and CEO of Harness. “This is exactly what our expanded work with Google Cloud directly addresses, giving joint customers a unified view of their software delivery environment and AI that can actually reason across it. When context is complete, speed and confidence go hand in hand.”

A Collaboration That Keeps Deepening

This integration is the latest evolution of a long-standing collaboration between Harness and Google Cloud. Harness AI runs on Gemini Enterprise Agent Platform, and joint customers already benefit from expanded access through Google Cloud Marketplace. With this announcement, that work expands from the infrastructure layer into the application layer — and directly into how AI understands and acts on the software delivery environment. And it doesn’t stop there. The Harness MCP Server is now accessible within Google’s Gemini Enterprise app environment, enabling Gemini Enterprise customers to leverage Harness capabilities directly from their existing AI interface.

“Google Cloud provides cutting-edge technology that helps partners innovate and deliver more impactful solutions for business transformation,” said Ritika Suri, Managing Director, AI and Data Partnerships at Google Cloud. “Through our partnership with Harness, we will provide customers with innovative capabilities that can improve operations, enhance customer experiences, and drive innovation.”

Join Us

As our Knowledge Graph ecosystem continues to grow, Harness remains committed to expanding the breadth of integrations available to customers with the goal of being the most comprehensive AI-ready software delivery platform on the market.

To connect with the Harness team in person, visit the Harness booth at Google Cloud Next.

About Harness
Harness is the AI Software Delivery Platform™ company, enabling engineering teams to build, test, and deliver software faster and more securely. Powered by Harness AI and the Software Delivery Knowledge Graph, the platform brings intelligent automation to every stage of the software delivery lifecycle after code — removing toil and freeing developers from manual, repetitive work. Companies like United Airlines, Morningstar, and Choice Hotels use Harness to deploy up to 70% faster, reduce change failure rates by 50%, cut deployment effort by 80%, and lower security noise by 65%. Based in San Francisco, Harness is backed by Menlo Ventures, IVP, Unusual Ventures, and Citi Ventures.

View original content to download multimedia:https://www.prnewswire.com/news-releases/harness-delivers-unified-ai-intelligence-across-software-delivery-with-google-cloud-302749850.html

SOURCE Harness

Continue Reading

Technology

H.I.G. Capital Announces the Sale of Celerion

Published

on

By

MIAMI, April 22, 2026 /PRNewswire/ — H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $74 billion of capital under management, is pleased to announce that one of its affiliates has signed a definitive agreement to sell its portfolio company, Celerion Holdings, Inc. (“Celerion” or the “Company”), a global CRO and leader in clinical pharmacology and bioanalytical sciences, to funds affiliated with THL Partners (“THL”).

Headquartered in Lincoln, Nebraska, Celerion is a leading provider of highly specialized clinical pharmacology and bioanalytical sciences with deep expertise in first-in-human dose escalation, cardiac safety (TQT), drug-drug interaction, and other complex clinical pharmacology studies that support regulatory approval and drug labeling. Celerion offers an integrated suite of services spanning data management, biostatistics, and clinical monitoring that supports a global base of pharmaceutical and biotechnology customers through its purpose-built clinical and laboratory infrastructure with facilities in Lincoln, Phoenix, Zurich, and Belfast.

H.I.G. acquired Celerion in November 2022 and worked closely with management to accelerate growth and strengthen the Company’s market position. During its ownership, H.I.G. supported strategic investments across commercial, operational, and technology initiatives, including the expansion of Celerion’s clinical and bioanalytical laboratory footprint. These efforts drove exceptional growth and solidified Celerion’s standing as a leading, clinical pharmacology-focused, contract research organization.

Susan Thornton, Celerion’s President & CEO, commented, “H.I.G. has been an exceptional partner to Celerion, helping us accelerate key strategic initiatives and invest meaningfully in our people, capabilities, and infrastructure. These efforts have strengthened our platform and enhanced the quality and consistency of outcomes we deliver to customers. We are excited to carry this momentum forward with THL as we enter our next phase of growth.”

Mike Gallagher, Managing Director at H.I.G., commented, “We are proud of what Celerion’s best-in-class team has accomplished during our partnership. The team has delivered industry- leading growth during our ownership, and we are confident it is uniquely positioned for its next chapter.”

Michael Kuritzky, Managing Director at H.I.G., added, “We are very proud of the work Celerion does to help drug sponsors worldwide navigate the complexities of clinical trial management. It has been a privilege to partner with Susan and her team, and we look forward to Celerion’s continued success.”

BofA Securities, Inc. and Lazard Frères & Co. LLC were financial advisors to H.I.G. and Celerion. McDermott Will & Schulte LLP was legal counsel for H.I.G. and Celerion in connection with the transaction.

About Celerion

Celerion is a clinical research organization that provides comprehensive clinical trial solutions to pharmaceutical and biotechnology clients conducting early clinical research throughout North America, Europe, and Asia. The Company serves its clients through a global network of facilities and provides first-in-human to proof-of-concept studies as well as bioanalytical laboratory services, data management and biometrics, and drug development services. For more information, visit celerion.com.

About H.I.G. Capital

H.I.G. Capital is a leading global alternative investment firm with $74 billion of capital under management.* Based in Miami, and with offices in Atlanta, Boston, Chicago, Los Angeles, New York, San Francisco, and Stamford in the United States, as well as international affiliate offices in Hamburg, London, Luxembourg, Madrid, Milan, Paris, Bogotá, Rio de Janeiro, São Paulo, Dubai, and Hong Kong, H.I.G. specializes in providing both debt and equity capital to middle market companies, utilizing a flexible and operationally focused/value-added approach:

H.I.G.’s equity funds invest in management buyouts, recapitalizations, and corporate carve-outs of both profitable as well as underperforming manufacturing and service businesses.H.I.G.’s debt funds invest in senior, unitranche, and junior debt financing to companies across the size spectrum, both on a primary (direct origination) basis, as well as in the secondary markets. H.I.G. also manages a publicly traded BDC, WhiteHorse Finance.H.I.G.’s real estate funds invest in value-added properties, which can benefit from improved asset management practices.H.I.G. Infrastructure focuses on making value-add and core plus investments in the infrastructure sector.

Since its founding in 1993, H.I.G. has invested in and managed more than 400 companies worldwide. The Firm’s current portfolio includes more than 100 companies with combined sales in excess of $53 billion. For more information, please refer to the H.I.G. website at hig.com.

*Based on total capital raised by H.I.G. Capital and its affiliates.

Contact:

Mike Gallagher
Managing Director
mgallagher@hig.com

Michael Kuritzky
Managing Director
mkuritzky@hig.com

Alex Zisson
Managing Director
azisson@hig.com

H.I.G. Capital
1450 Brickell Avenue
31st Floor
Miami, FL 33131
P: 305.379.2322
hig.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/hig-capital-announces-the-sale-of-celerion-302749396.html

SOURCE H.I.G. Capital

Continue Reading

Trending